Literature DB >> 26463037

Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-κB pathways in human lung epithelial cells.

Chien-Huang Lin1, Chung-Hung Shih2, Bing-Chang Chen3.   

Abstract

Airway inflammation plays a major role in the pathophysiology of lung inflammatory diseases such as asthma. Thrombin, a serine protease, is known to mediate central functions in thrombosis and hemostasis and also plays a critical role in lung inflammation via producing chemokine release including interleukin (IL)-8/CXCL8. Our previous studies showed that c-Src- and Rac-dependent nuclear factor (NF)-κB signaling pathways participate in thrombin-induced IL-8/CXCL8 release in human lung epithelial cells. In this study, we further investigated the role of casein kinase 2 (CK2)/mitogen stress-activated protein kinase 1 (MSK1)-dependent p65 phosphorylation in thrombin-induced NF-κB activation and IL-8/CXCL8 release. Thrombin-induced IL-8/CXCL8 release was inhibited by CK2 inhibitors (apigenin and tetrabromobenzotriazole, TBB), small interfering RNA of CK2β (CK2β siRNA), and MSK1 siRNA. Treatment of cells with thrombin caused increases in CK2β phosphorylation at Ser209, which was inhibited by a protein kinase C α (PKCα) inhibitor (Ro-32-0432). Thrombin-induced MSK1 phosphorylation at Ser581 and Akt phosphorylation at Ser473 were inhibited by apigenin. Moreover, the thrombin-induced increase in IL-8/CXCL8 release was attenuated by p65 siRNA. Stimulation of cells with thrombin resulted in an increase in p65 phosphorylation at Ser276, which was inhibited by apigenin and MSK1 siRNA. Thrombin-induced κB-luciferase activity was also inhibited by apigenin and MSK1 siRNA. Taken together, these results show that thrombin activates the PKCα/CK2/MSK1 signaling pathways, which in turn initiates p65 phosphorylation and NF-κB activation, and ultimately induces IL-8/CXCL8 release in human lung epithelial cells.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Casein kinase 2 (CK2); IL-8/CXCL8; Lung inflammation; Mitogen stress-activated protein kinase 1 (MSK1); Thrombin; p65

Mesh:

Substances:

Year:  2015        PMID: 26463037     DOI: 10.1016/j.ejphar.2015.10.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Respiratory Mucosal Proteome Quantification in Human Influenza Infections.

Authors:  Tony Marion; Husni Elbahesh; Paul G Thomas; John P DeVincenzo; Richard Webby; Klaus Schughart
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

2.  Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts.

Authors:  Weili Hui; Chenqi Zhao; Sylvain G Bourgoin
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

3.  Time-resolved mRNA and miRNA expression profiling reveals crucial coregulation of molecular pathways involved in epithelial-pneumococcal interactions.

Authors:  Haiyan Li; Li Lin; Lei Chong; Shuge Gu; Shunhang Wen; Gang Yu; Xiaoguang Hu; Lin Dong; Hailin Zhang; Changchong Li
Journal:  Immunol Cell Biol       Date:  2020-07-20       Impact factor: 5.126

4.  Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent.

Authors:  Haimei Zhu; Yuji Wang; Ce Song; Qiqi Feng; Jianhui Wu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-07-19

Review 5.  The role of cigarette smoke-induced epigenetic alterations in inflammation.

Authors:  Dandan Zong; Xiangming Liu; Jinhua Li; Ruoyun Ouyang; Ping Chen
Journal:  Epigenetics Chromatin       Date:  2019-11-11       Impact factor: 4.954

6.  LTB4 Promotes Acute Lung Injury via Upregulating the PLCε-1/TLR4/NF-κB Pathway in One-Lung Ventilation.

Authors:  Jing Luo; Qingjie Ma; Heng Tang; Xi Zou; Xin Guo; Yuzhen Hu; Kejiang Zhou; Rui Liu
Journal:  Dis Markers       Date:  2022-01-11       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.